The heart in transfusion dependent homozygous thalassaemia today - Prediction, prevention and management

European Journal of Haematology

Volumn 80, Issue 2, 2008, Pages 93-106

  Aessopos, Athanassios ^a   Berdoukas, Vasilios ^a   Tsironi, Maria ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cardiac failure; Cardiomyopathy; Iron chelation therapy; Thalassaemia major; Transfusion therapy

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CARVEDILOL; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HEPCIDIN; SPIRONOLACTONE;

BLOOD TRANSFUSION; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENTIATION; ENDOCRINE DISEASE; HEART ARRHYTHMIA; HISTOPATHOLOGY; HUMAN; HYPOCALCEMIA; HYPOPARATHYROIDISM; INFECTION; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; LABORATORY TEST; LONG TERM CARE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERICARDITIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; THALASSEMIA;

ADULT; AUTOPSY; BETA-THALASSEMIA; BLOOD TRANSFUSION; CARBON MONOXIDE; CHELATING AGENTS; FERRITINS; HEART; HEMOGLOBINS; HOMOZYGOTE; HUMANS; IRON; IRON OVERLOAD; MALE;

EID: 38049113365     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.01018.x     Document Type: Review

References (103)

1. Modell B, Khan M, Darlison M. Survival in beta-thalassemia major in the UK: data from the UK Thalassemia Register. Lancet 2000 355 : 2051 2.
2. Borgna-Pignatti C, Rigolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and desferrioxamine. Haematologica 2004 89 : 1187 93.
3. Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, refractory anemia with hemochromatosis. Circulation 1964 30 : 698 705.
4. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004 104 : 263 9.
5. Caro JJ, Ward A, Green TC, Huybrechts K, Arana A, Wait S, Eleftheriou A. Impact of thalassemia major on patients and their families acta. Haematologica 2002 107 : 150 7.
6. Aessopos A, Farmakis D, Hatziliami A, Fragodimitri C, Karabatsos F, Joussef J, Mitilineou E, Diamanti-Kandaraki E, Meletis J, Karagiorga M. Cardiac status in well- treated patients with thalassemia major. Eur J Haematol 2004 73 : 359 66.
7. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous beta-thalassemia. NEJM 1994 331 : 574 8.
8. Nemeth E, Ganz T. Hepcidin and iron-loading anemias. Haematologica 2006 91 : 727 32.
9. Papanicolaou G, Tzilianos M, Christakis J, Bogdanos D, Tsimirika K, MacFarlane J, Goldberg YP, Sakellaropoulos N, Ganz T, Nemeth E. Hepcidin in iron overload disorders. Blood 2005 105 : 4103 5.
10. Gardenghi S, Marongiu MF, Ramos P, et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood 2007 109 : 5027 35.
11. Oudit GY, Trivieri MG, Khaper N, Liu PP, Backx PH. Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med 2006 84 : 349 64. Epub 2006 Apr 8.
12. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003 102 : 2670 7.
13. Glickstein H, El RB, Link G, Breuer W, Konijn AM, Hershko C, Nick H, Cabantchik ZI. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 2006 108 : 3195 203.
14. Kim E, Giri SN, Pessah IN. Iron(II) is a modulator of ryanodine-sensitive calcium channels of cardiac muscle sarcoplasmic reticulum. Toxicol Appl Pharmacol 1995 130 : 57 66.
15. Scoote M, Williams AJ. The cardiac ryanodine receptor (calcium release channel): emerging role in heart failure and arrhythmiapathogenesis. Cardiovasc Res 2002 56 : 359 72.
16. Trinder D, Fox C, Vautier G, Olynyk JK. Molecular pathogenesis of iron overload. Gut 2002 51 : 290 5.
17. Economou-Petersen E, Aessopos A, Kladi A, et al. Apolipoprotein E epsilon4 allele as a genetic risk factor for left ventricular failure in homozygous beta-thalassemia. Blood 1998 92 : 3455 9.
18. Ferrara M, Matarese SM, Francese M, Borrelli B, Coppola L, Coppola A, Iarussi D, Esposito L. Role of apolipoprotein E (APOE) polymorphism on left cardiac failure in homozygous beta thalassaemic patients. Br J Haematol 2001 114 : 959 60.
19. Kang-Hsi W, Jan-Gowth C, Yung-Jen H, Shu-Fen W, Ching-Tien P. Glutathione S-Transferase M1 Gene Polymorphisms are associated with cardiac iron deposition in patient's with -thalassemia major. Hemoglobin 2006 30 : 251 6.
20. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2* magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001 22 : 2171 9.
21. Wood JC, Tyszka M, Carson S, Nelson M, Coates T. Myocardial iron loading in transfusion dependent thalassemia and sickle-cell disease. Blood 2003 103 : 1934 6.
22. Aessopos A, Fragodimitri C, Karabatsos F, Hatziliami A, Yousef J, Giakoumis A, Dokou A, Gotsis ED, Berdoukas V, Karagiorga M. Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. Haematologica 2007 92 : 131 2.
23. Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Nair S, Anderson LJ, Walker JM, Pennell DJ. Myocardial iron loading in patients with thalassemia major on desferrioxamine chelation. J Cardiovasc Magn Reson 2006 8 : 543 7.
24. Farmakis D, Giakoumis A, Polymeropoulos E, Aessopos A. Pathogenetic aspects of immune deficiency associated with beta-thalassemia. Med Sci Monit 2003 9 : RA19 22.
25. Walker EM, Walker SM. Effects of iron overload on the immune system. Ann Clin Lab Sci 2000 30 : 354 65.
26. Lesic B, Foulon J, Carniel E. Comparison of the effects of deferiprone versus desferrioxamine on growth and virulence of yersinia enterocolitica. Antimicrob Agents Chemother 2002 46 : 1741 5.
27. Khimji PL, Miles AA. Microbial iron-chelators and their action on Klebsiella infections in the skin of guinea-pigs. Br J Exp Pathol 1978 59 : 137 47.
28. Kremastinos DT, Flevari P, Spyropoulou M, Vrettou H, Tsiapras D, Stavropoulos-Giokas CG. Association of heart failure in homozygous beta-thalassemia with the major histocompatibility complex. Circulation 1999 100 : 2074 8.
29. Kremastinos DT, Tsetsos GA, Tsiapras DP, Karavolias GK, Ladis VA, Kattamis CA. Heart failure in beta thalassemia: a 5-year follow-up study. Am J Med 2001 111 : 349 54.
30. Cheung YF, Chan GC, Ha SY. Arterial stiffness and endothelial function in patients with beta-thalassemia major. Circulation 2002 106 : 2561 6.
31. Tsomi K, Karagiorga-Lagana M, Karabatsos F, Fragodimitri C, van Vliet-Konstantinidou C, Premetis E, Stamoulakatou A. Arterial elastorrhexis in beta-thalassaemia intermedia, sickle cell thalassaemia and hereditary spherocytosis. Eur J Haematol 2001 67 : 135 41.
32. Aessopos A, Farmakis D, Loukopoulos D. Elastic tissue abnormalities resembling pseudoxanthoma elasticum in beta thalassemia and the sickling syndromes. Blood 2002 99 : 30 5. Review.
33. Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006 107 : 2279 85.
34. Aessopos A, Farmakis D. Pulmonary hypertension in beta-thalassemia. Ann N Y Acad Sci 2005 1054 : 342 9. Review.
35. Derchi G, Forni GL, Formisano F, Cappellini MD, Galanello R, D'Ascola G, Bina P, Magnano C, Lamagna M. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica 2005 90 : 452 8.
36. Tsironi M, Korovesis K, Farmakis D, Deftereos S, Aessopos A. Hypocalcemic heart failure in thalassemic patients. Int J Hematol 2006 83 : 314 7.
37. Nienhuis AW. Vitamin C and iron. N Engl J Med 1981 304 : 170 1.
38. Braunwald E. Heart Disease. W.B. Saunders, Philadelphia, 1997. 5th edn, pp. 1786.
39. Varat MA, Adolph RJ, Fowler NO. Cardiovascular effect of anemia. Am Heart J 1972 83 : 415.
40. Asimacopoulos PJ, Groves MD, Fischer DK, Wierman AM, Katras T, Safi HJ, Verani MS. Pernicious anemia manifesting as angina pectoris. South Med J 1994 87 : 671.
41. Aessopos A, Deftereos S, Farmakis D, Corovesis C, Tassiopoulos S, Tsironi M, Georgonikou D, Moyssakis J. Cardiovascular adaptation to chronic anemia in the elderly: an echocardiographic study. Clin Invest Med 2004 27 : 265 73.
42. Aessopos A, Farmakis D, Deftereos S, Tsironi M, Polonifi A, Moyssakis I, Diamanti-Kandaraki E, Papalambros E. Cardiovascular effects of splenomegaly and splenectomy in beta-thalassemia. Ann Hematol 2005 84 : 353 7.
43. Murray JF, Dawson AM, Sherlock S. Circulatory changes in chronic liver diseases. Am J Med 1958 24 : 358 67.
44. Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis I, Karagiorga M. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest 2005 127 : 1523 30.
45. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with desferrioxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007 115 : 1876 84. Epub 2007 Mar 19.
46. Buja LM, Roberts WC. Iron in the heart. Etiology and clinical significance. Am J Med 1971 51 : 209 21.
47. Sanyal SK, Johnson W, Jayalakshmamma B, Green AA. Fatal "iron heart" in an adolescent: biochemical and ultrastructural aspects of the heart. Pediatrics 1975 55 : 336 41.
48. Modell B, Berdoukas V. The Clinical Approach to Thalassaemia. Grune and Stratton, New York, 1984 165 9.
49. Forni GL, Derchi G. Typical manifestation of acute congestive heart failure in patients with thalassemia major causing diagnostic delay in the emergency room. The European Journal of Heart Failure 2003 5 : 607 8.
50. Hahalis G, Manolis AS, Gerasimidou I, Alexopoulos D, Sitafidis G, Kourakli A, Körfer R, Koerner MM, Vagenakis AG, Zoumbos NC. Right ventricular diastolic function in beta-thalassemia major: echocardiographic and clinical correlates. Am Heart J 2001 141 : 428 34.
51. Hahalis G, Manolis AS, Apostolopoulos D, Alexopoulos D, Vagenakis AG, Zoumbos NC. Right ventricular cardiomyopathy in beta-thalassaemia major. Eur Heart J 2002 23 : 147 56.
52. Aessopos A, Farmakis D, Karagiorga M, Rombos I, Loucopoulos D. Pseudoxanthoma elasticum lesions and cardiac complications as contributing factors for strokes in beta-thalassemia patients. Stroke 1997 28 : 2421 4.
53. Venti S, Cainelli F, Cesario F. Infections and thalassaemia. Lancet Infect Dis 2006 6 : 226 33.
54. Sermsappasuk P, Baek M, Weiss M. Kinetic analysis of myocardial uptake and negative inotropic effect of amiodarone in rat heart. Eur J Pharm Sci 2006 28 : 243 8.
55. Grady RW, Berdoukas VA, Rachmielewitz EA, Galanello R, Borgna-Pignatti C, Giardina RJ. Optimizing chelation therapy: Combining deferiprone and desferrioxamine. Dec 2000. 42nd Annual Meeting of the American Society of Hematology, San Fransisco Abstract)
56. Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessì C, Leoni G, Muroni PP, Galanello R. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005 90 : 1309 14.
57. Kontoghiorghes GJ. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, desferrioxamine, ICL670, GT56-252, L1NAll and starch desferrioxamine polymers. Hemoglobin 2006 3 : 329 47.
58. Tsironi M, Deftereos S, Andriopoulos P, Farmakis D, Meletis J, Aessopos A. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. Eur J Haematol 2005 74 : 84 5.
59. Tsironi M, Polonifi K, Deftereos S, Farmakis D, Andriopoulos P, Moyssakis I, Aessopos A. Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia. Eur J Haematol 2005 75 : 355 8.
60. Wu K-H, Chang JS, Tsai CVH, Peng CT. Combined therapy with deferiprone and desferrioxamine successfully regresses heart failure in patients with β-thalassaemia major. Ann Haematol 2004 83 : 471 3.
61. Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. Br J Haematol 2006 134 : 438 44.
62. Christoforidis A, Perifanis V, Athanassiou-Metaxa M. Combined chelation therapy improves glucose metabolism in patients with beta-thalassaemia major. Br J Haematol 2006 135 : 271 2.
63. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassemia. Lancet 2002 360 : 516 20.
64. Davis BA, Porter JB. Long-term outcome of continuous 24-hour desferrioxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000 95 : 1229 36.
65. Chopra D, Janson P, Sawin C. Insensitivity to digoxin associated with hypocalcemia. N Engl J Med 1977 296 : 917 8.
66. Masera G, Terzoli S, Avanzini A, Fontanelli G, Mauri RA, Piacentini G, Ferrari M. Evaluation of the supertransfusion regimen in homozygous beta-thalassaemia children. Br J Haemat 1982 52 : 111 3.
67. Cazzola M, De Stefano P, Ponchio L, Locatelli F, Beguin Y, Dessi C, Barella S, Cao A, Galanello R. Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major. Br J Haematol 1995 89 : 473 8.
68. Pinna AD, Argiolu F, Marongiu L, Pinna DC. Indications and results for splenectomy for beta thalassemia in two hundred and twenty-one pediatric patients. Surg Gynecol Obstetric 1988 167 : 109 13.
69. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of beta-thalassemia major in North America. Blood 2004 104 : 34 9.
70. Kattamis C, ed. Iron Overload and Chelation in Thalassemia. Hans Huber Publishers, Bern, 1987.
71. Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000 110 : 971 7.
72. Chapman RW, Hussain MA, Gorman A, Laulicht M, Politis D, Flynn DM, Sherlock S, Hoffbrand AV. Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta-thalassaemia major and iron overload. J Clin Pathol 1982 35 : 487 91.
73. Cazzola M, Borgna-Pignatti C, de Stefano P, Bergamaschi G, Bongo IG, Dezza L, Avato F. Internal distribution of excess iron and sources of serum ferritin in patients with thalassemia. Scand J Haematol 1983 30 : 289 96.
74. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Walker JM, Pennell DJ. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous deseferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haemat 2004 127 : 348 55.
75. Bircher J, Benhamon J-P, McIntyre N, Rizzetto M. Rodes - Editors Oxford Textbook of Clinical Hepatology. Oxford Univ Press, New York, 1999, 2nd edn. Vol. 2, 1862.
76. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C. Hepatic iron concentration and total body iron stores in thalassaemia major. N Engl J Med 2000 343 : 327 31.
77. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997 89 : 739 61.
78. Berdoukas V, Dakin C, Freema A, Fraser I, Aessopos A, Bohane T. Lack of correlation between iron overload cardiac dysfunction and needle liver biopsy iron concentration. Haematologica 2005 90 : 685 6.
79. Cabantchik ZI, Glickstein H, Milgram P, Breuer W. A fluorescence assay for assessing chelation of intracellular iron in a membrane model system and in mammalian cells. Annal Bioch 1996 233 : 221 7.
80. Pepe A, Positano V, Santarelli MF, Sorrentino F, Cracolici E, De Marchi D, Maggio A, Midiri M, Landini L, Lombardi M. Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. J Magn Reson Imaging 2006 23 : 662 8.
81. Aessopos A, Deftereos S, Tsironi M, Karabatsos F, Yousef J, Fragodimitri C, et al. Predictive echo-Doppler indices of left ventricular impairment in B-thalassemic patients. Ann Hematol 2007 86 : 429 34.
82. Spirito P, Lupi G, Melevendi C, Vecchio C. Restrictive diastolic abnormalities identified by Doppler echocardiography in patients with thalassemia major. Circulation 1990 82 : 88 94.
83. Kremastinos DT, Tsiapras DP, Tsetsos GA, Rentoukas EI, Vretou HP, Toutouzas PK. Left ventricular diastolic Doppler characteristics in beta-thalassemia major. Circulation 1993 88 : 1127 35.
84. Iarussi D, Di Salvo G, Pergola V, Coppolino P, Tedesco MA, Ratti G, Esposito L, Calabrò R, Ferrara M. Pulsed Doppler tissue imaging and myocardial function in thalassemia major. Heart Vessels 2003 18 : 1 6.
85. Hou JW, Wu MH, Lin KH, Lue HC. Prognostic significance of left ventricular diastolic indexes in beta-thalassemia major. Arch Pediatr Adolesc Med 1994 148 : 862 6.
86. Vogel M, Anderson LJ, Holden S, Deanfield JE, Pennell DJ, Walker JM. Tissue Doppler echocardiography in patients with thalassaemia detects early myocardial dysfunction related to myocardial iron overload. Eur Heart J 2003 24 : 113 9.
87. Aessopos A, Giakoumis A, Fragodimitri C, Karabatsos F, Hatziliami A, Yousef J, Gotsis E, Berdoukas V, Karagiorga M. Correlation of echocardiography parameters with cardiac magnetic resonance imaging in transfusion-dependent thalassaemia major. Eur J Haematol 2007 78 : 58 65.
88. Leon MB, Borer JS, Bacharach SL, Green MV, Benz EJ Jr., Griffith P, Nienhuis AW. Detection of early cardiac dysfunction in patients with severe beta-thalassemia and chronic iron overload. N Engl J Med 1979 301 : 1143.
89. Freeman AP, Giles RW, Berdoukas VA, Walsh WF, Choy D, Murray PC. Early left ventricular dysfunction and chelation therapy in thalassaemia major. Ann Intern Med 1983 99 : 450 4.
90. Aessopos A, Farmakis D, Polonifi A, Tsironi M, Fragodimitri C, Hatziliami A, Karagiorga M, Diamanti-Kandarakis E. Plasma B-type natriuretic peptide concentration in beta-thalassaemia patients. Eur J Heart Fail 2007 9 : 537 41.
91. Barosi G, Arbustini E, Gavazzi A, Grasso M, Pucci A. Myocardial iron grading by Endomyocardial biopsy. A clinico-pathologic study on iron overloaded patients. Eur J Haematol 1989 42 : 382 8.
92. Fitchett DH, Coltart DJ, Littler WA, Leyland MJ, Trueman T, Gozzard DI, Peters TJ. Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium. Cardiovasc Res 1980 14 : 719 24.
93. Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle-cell disease patients. Blood 2005 106 : 1460 5.
94. Voskaridou E, Douskou M, Terpos E, Papassotiriou I, Stamoulakatou A, Ourailidis A, Loutradi A, Loukopoulos D. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassemia and sickle cell disease. BJH 2004 126 : 736 42.
95. Ooi GC, Khong PL, Chan GCF, Chan KN, Chan KL, Lam W, Ng I, Ha SY. Magnetic resonance screening of iron status in transfusion-dependent β-thalassemia patients. BJH 2004 124 : 385 90.
96. Olivieri NF, Brittenham GM, Armstrong SAM, et al. First prospective randomised trial of the iron chelators Deferiprone (L1) and Desferrioxamine. Blood 1995 86 : 249a.
97. Westwood MA, Firmin DN, Gildo M, Stathis G, Markissia K, Vasili B, Pennell DJ. Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemi. Int J Cardiovasc Imaging (US) 2005 21 : 531 8.
98. Ghugre NR, Enriquez CM, Coates TD, Nelson MD Jr., Wood JC. Improved R2* measurements in myocardial iron overload. J Magn Reson Imaging 2006 23 : 9 16.
99. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or desferrioxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006 107 : 3738 44.
100. Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH. Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan. Eur J Haematol 2003 70 : 392 7.
101. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006 107 : 3455 62. Epub 2005 Dec 13.
102. Eleftheriou P, Tanner M, Pennell D, Porter J. Response of Myocardial T2* to oral deferasirox montherapy for 1 year in 29 patients with transfusion-dependent anaemias; A subgroup analysis. European Haematology Association Annual General Meeting, Abstract 0999, 2006.
103. Wood JC, Otto-Duessel M, Gonzalez I, Aguilar MI, Shimada H, Nick H, Nelson M, Moats R. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res 2006 148 : 272 80.